GreinDX is a groundbreaking brand that is revolutionizing cancer detection and increasing survival rates. They are developing a unique and proprietary bench-top system that can capture and study circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and circulating tumor antigens (CTA) from a single blood sample or other body fluids. Unlike traditional tumor biopsies, their liquid biopsy approach is non-invasive and eliminates the need for surgery or needles.

This innovative technology allows for the detection of cancer earlier, monitoring for relapse, and identifying the need for alternative treatments. It is expected to become a critical factor in future diagnostic, prognostic, and personalized therapeutic cancer programs. GreinDX's solution is based on a porous surface of crystalline material and short proprietary peptides tailored to specific biomarkers.

Their bench-top system enables precise fluid separation, sorting, and capture of cancer-specific macromolecules, which can then be further investigated through PCR or biochemical analysis. With a mission to make early cancer detection available to everyone, GreinDX is led by a multidisciplinary team of experts and supported by prestigious partners in the medical field. They aim to disrupt the current precision and personalized cancer medicine workflow, bringing significant benefits to patients.

Join GreinDX on their journey to advance cancer detection and improve outcomes for patients worldwide